The proteolytic processing pattern of pro-ACTH/endorphin in rat hypothalamus is similar to the pattern in the pars intermedia; peptides the size of 8-endorphin, */-lipotropin (v-LPH), corticotropin-like intermediate lobe peptide (CLIP), a-melanotropin (?I-MSH), joining peptide, and glycosylated r,-MSH all represent predominant end products. Equimolar amounts of &endorphin-, a-MSH-, CLIP-, T-LPH-, and joining peptiderelated immunoreactivity are found in hypothalamic extracts (-3 pmol per hypothalamus). Although the proteolytic processing pattern in the hypothalamus is similar to that in the pars intermedia, a tissue-specific posttranslational processing pattern was detected. Ion-exchange analysis of &endorphin-sized immunoreactive material from hypothalamic extracts resolves three major forms, corresponding to &endorphin(l-31), &en-dorphin( l-27), and &endorphin( 1-26). The a-iV-acetylated forms of endorphin represent less than 10% of the total /?-endorphin immunoreactivity. Analyses of hypothalamic a-MSHsized molecules with acetyl-and amide-directed a-MSH antisera suggest that hypothalamic a-MSH is fully amidated, but largely not a-l\r-acetylated. Fractionation by reverse-phase highperformance liquid chromatography (HPLC) confirms that > 85% of the a-MSH immunoreactivity corresponds to ACTH( l-13)NH, or its sulfoxide, and less than 10% corresponds to a-MSH [a-N-acetyl-ACTH(l-13) NH,] or its sulfoxide. Isoelectric focusing demonstrates that 83-93% of hypothalamic CLIP is phosphorylated. Isoelectric focusing suggests that the majority of the hypothalamic y-LPH-sized immunoreactive material is indistinguishable from */-LPH synthesized by pituitary melanotropes. The minor extent of a-iV-acetylation of a-MSH and &endorphin, the limited carboxyl-terminal proteolysis of &en-dorphin, and the extensive phosphorylation of CLIP represent major differences between the posttranslational processing patterns of pro-ACTH/endorphin in the hypothalamus and pars intermedia.
The proteolytic processing pattern of pro-ACTH/endorphin in rat hypothalamus is similar to the pattern in the pars intermedia; peptides the size of 8-endorphin, */-lipotropin (v-LPH), corticotropin-like intermediate lobe peptide (CLIP), a-melanotropin (?I-MSH), joining peptide, and glycosylated r,-MSH all represent predominant end products. Equimolar amounts of &endorphin-, a-MSH-, CLIP-, T-LPH-, and joining peptiderelated immunoreactivity are found in hypothalamic extracts (-3 pmol per hypothalamus). Although the proteolytic processing pattern in the hypothalamus is similar to that in the pars intermedia, a tissue-specific posttranslational processing pattern was detected. Ion-exchange analysis of &endorphin-sized immunoreactive material from hypothalamic extracts resolves three major forms, corresponding to &endorphin(l-31), &en-dorphin( l-27), and &endorphin( 1-26). The a-iV-acetylated forms of endorphin represent less than 10% of the total /?-endorphin immunoreactivity. Analyses of hypothalamic a-MSHsized molecules with acetyl-and amide-directed a-MSH antisera suggest that hypothalamic a-MSH is fully amidated, but largely not a-l\r-acetylated. Fractionation by reverse-phase highperformance liquid chromatography (HPLC) confirms that > 85% of the a-MSH immunoreactivity corresponds to ACTH( l-13)NH, or its sulfoxide, and less than 10% corresponds to a-MSH [a-N-acetyl-ACTH(l-13) NH,] or its sulfoxide. Isoelectric focusing demonstrates that 83-93% of hypothalamic CLIP is phosphorylated. Isoelectric focusing suggests that the majority of the hypothalamic y-LPH-sized immunoreactive material is indistinguishable from */-LPH synthesized by pituitary melanotropes. The minor extent of a-iV-acetylation of a-MSH and &endorphin, the limited carboxyl-terminal proteolysis of &en-dorphin, and the extensive phosphorylation of CLIP represent major differences between the posttranslational processing patterns of pro-ACTH/endorphin in the hypothalamus and pars intermedia.
Adrenocorticotropin (ACTH) and P-lipotropin (P-LPH) are synthesized as parts of a larger common precursor molecule [pro-ACTH/endorphin or pro-opiomelanocortin (POMC)], which is posttranslationally processed, in a tissue-specific manner, to yield differing end products in the anterior and intermediate lobes of the pituitary. The co-and posttranslational modifications involved in the processing of this 30 kDa precursor protein include defined and ordered proteolysis, glycosylation, phosphorylation, a-N-acetylation and a-amidation (Bennett et al., 1982; Browne et al., 198 la, b; Douglass et al., 1984; Mains, 1980, 1982; Krieger et al., 1980; Rudman et al., 1979; Seidah and Chretien, 198 1; Zakarian and Smyth, 1982a, b) .
Extensive immunohistochemical mapping studies utilizing antisera raised against several pituitary ACTH/endorphin-derived peptides have characterized a large number of neuronal pathways containing antigenic determinants of the ACTH/endorphin system throughout the mammalian brain (Bloom et al., 1980; Joseph, 1980; Oliver and Porter, 1978; Pelletier, 1979; Schwartzberg and Nakane, 1982; Watson et al., 1978; Zimmerman et al., 1978) . Although immunoreactive fibers are found in many regions of the forebrain and brain stem, there is general agreement that positively staining cell bodies are located exclusively in the arcuate nucleus of the hypothalamus and the dorsal caudal medulla in the region of the nucleus of the solitary tract (Khachaturian et al., 1983; Romagnano and Joseph, 1983; Schwartzberg and Nakane, 1983) .
The structure of the single gene that codes for pro-ACTH/ endorphin within the rat genome (Drouin and Goodman, 1980; Drouin et al., 1983) suggests that any differences that exist between ACTH/endorphin-derived peptides from multiple tissues are the result of tissue-specific posttranslational processing rather than the result of expression of two different genes. Recent studies have demonstrated that, at the level of gel filtration, the processing of pro-ACTH/endorphin-derived peptides in rat hypothalamus more closely resembles the pattern for proteolytic processing in the pars intermedia than in the pars distalis, with both a-melanotropin (a-MSH) and @-endorphin-sized material representing the predominant end products (Bamea et al., 1982; Dennis et al., 1983a; Gramsch et al., 1980; Loh et al., 1980; Orwoll et al., 1979) ; a summary of the nomenclature for pro-ACTH/endorphin-derived peptides is shown in Figure 9 . In the intermediate lobe of the pituitary, a-MSH-like material has been shown to exist in three distinct forms differing in their degree of acetylation. Although a-N,O-diacetyl-a-MSH represents the major form of a-MSH synthesized by rat pituitary melanotropes (Browne et al., 1981a; Glembotski, 1982; Rudman et al., 1979) , there is disagreement over the acetylation state of hypothalamic a-MSH-like material (Evans et al., 1982; Geis et al., 1984; Loh et al., 1980; O'Donohue et al., 1981) .
Previous studies have shown that the major forms of ,&en-dorphin in the rat intermediate pituitary are the a-N-acetylated derivatives of &endorphin( l-26) and &endorphin( l-27) whereas the major form produced by the anterior lobe corticotropes is ,&endorphin( l-3 1) (Akil et al., 198 1; Bennett et al., 1983; Eipper and Mains, 1981; Weber et al., 1981; Zakarian and Smyth, 1982a, b) . There is still considerable controversy, however, over the extent of a-N-acetylation (Weber et al., 198 1; Zakarian and Smyth, 1982a, b) and carboxyl-terminal proteolysis (Dennis et al., 1983a, b; Liotta et al., 1984; Zakarian and Smyth, 1982a, b) of B-endorphin in the rat brain.
Previous studies on the posttranslational processing of corticotropin-like intermediate lobe peptide (CLIP) by rat pituitary melanotropes have demonstrated that, in addition to the proteolytic cleavages that produce CLIP from ACTH, there are further modifications to which CLIP is subjected, including phosphorylation, N-linked glycosylation, and removal of the carboxyl-terminal phenylalanine residue (Bennett et al., 1982; Eipper and Mains, 1982) . Previous studies on the biochemical characterization of hypothalamic CLIP have demonstrated multiple peaks of CLIP-related immunoreactivity upon reversephase (RP) HPLC analysis, suggesting the occurrence of posttranslational modifications similar to those occurring in the pars intermedia (Liotta and Krieger, 1983a; Smith et al., 1982; Turner et al., 1983) .
The demonstration of ACTH/endorphin-derived molecules in multiple tissues, with the potential of posttranslational modification into products both similar to and different from those elaborated by the anterior and intermediate pituitary lobes, has raised a number of fundamental questions with regard to the chemical nature, biosynthetic pathway, regulation, and function(s) of these peptide products in the different tissues in which they can be found. Since the various peptide products derived from a single precursor molecule are released in a coordinated fashion (Liston and Rossier, 1984; Mains and Eipper, 1979; Tager et al., 1975) , and each may interact independently with an appropriate target tissue or modulate the effects of another peptide product with such a target tissue (Farese et al., 1983; O'Donohue et al., 1981; Pedersen et al., 1980; Scheller et al., 1984; Walker et al., 1980) a coordinated study on the quantitation and biochemical characterization of hypothalamic pro-ACTH/endorphin-derived peptides was undertaken.
Materials and Methods Tissue extraction and sample preparation
Adult male Sprague-Dawley rats (125-250 gm) were used for all experiments. The animals were decapitated and the whole brains were rapidly removed. Hypothalamic tissue (-25 mg per hypothalamus) was excised and homogenized by hand in 5 volumes (wt/vol) of 1% trifluoroacetic acid, 1 M HCl, 5% formic acid, and 1% NaCl (Bennett et al., 1978) by means of a conical glass homogenizer with ground-glass pestle. The boundaries of the hypothalamic fragment extended from the anterior margin of the preoptic area to the anterior border of the mammillary bodies. Extracts were frozen and thawed twice and centrifuged at 1500 x g for 15 min at 4°C to remove insoluble material. The supematants were removed and the pellets were reextracted by resuspension in l-2 ml TFA/HCl/HCOOH/NaCl and then centrifugation; the supematants were pooled.
Tissue extracts were cycled five times onto a C,, Sep-Pak cartridge (Waters Associates), washed with 20 ml 0.1% trifluoroacetic acid and eluted with 4 ml 80% acetonitrile in 0.1% trifluoroacetic acid (Bennett et al., 198 1 b) ; 1 mg BSA was added to the Sep-Pak eluate as a carrier protein. The tissue extracts were dried under reduced pressure after addition of 2-mercaptoethanol (l%).
Gel filtration
For gel filtration using , tissue extracts were redissolved in 50% acetic acid containing 5% 2-mercaptoethanol; the Sephadex G-75 column (0.9 x 58 cm) was eluted with 10% formic acid, 20 &ml bovine serum albumin, and 0. II 2-mercaptoethanol (Eipper and Mains, 1982; Glembotski, 1982) . For HPLC gel filtration, tissue extracts were redissolved in 250 ~1 of 32% acetonitrile containing 0.1% trifluoroacetic acid; the samples were applied to a Bio-Sil TSK-400 column (7.5 x 300 mm) connected in series to a Bio-Sil TSK-250 (7.5 x 300 mm) and a Bio-Sil TSK-125 (7.5 x 300 mm) column (Bio-Rad). The columns were eluted with 32% acetonitrile in 0.1% trifluoroacetic acid (Bennett et al., 198 1 b; Eipper et al., 1983) at a flow rate of 1 ml/ min. The elution times of several standard proteins and synthetic peptides were determined by monitoring absorbance at 220 nm. Recoveries, determined bv the use of various )H-labeled pro-ACTH/endoruhinderived peptihes purified from primary cultures of rat intermediate pituitary or mouse corticotropic tumor cells (Keutmann et al., 1981) , were in excess of 90%.
Radioimmunoassays
Radioimmunoassays for P-endorphin utilized antiserum Danielle [specific for fl-endorphin( 10-19); Mains and Eipper, 19791 . Radioimmunoassays for a-MSH utilized antiserum Ann [a general ACTH( 1-13) assay; Glembotski, 19821, antiserum Annette [an amide-directed a-MSH assay; Eipper et al., 19831, and antiserum Patti [an acetyl-directed (Y-MSH assay; Eipper et al., 19831 . Radioimmunoassays for CLIP [ACTH( 18139)] utilized antiserum -Kathy [specific for ACTH(34-39); Mains and EiDDer. 19831 . Antiserum Kathy showed less than 0.2% M cross-reactivitywith ACTH(7-38) compared with either hACTH( l-39) or ACTH( 18-39), demonstrating the necessity of the carboxyl-terminal phenylalanine residue for full cross-reactivity. Radioimmunoassays for y-LPH utilized antiserum Henrietta; as reported previously for rat pituitary , immunoassays for rat hypothalamic r-LPH-related peptides utilizing mouse /3-lipotropin as a radiolabeled trace and standard showed nonparallel displacement.
In order to quantitate the relative levels of y-LPH-related molecules in gel filtration fractions, the amount of each fraction to be assayed was varied so that the actual amount of '251-&,,-LPH (mouse @-lipotropin) displaced by each sample was similar. All assays were performed as previously described.
Radioimmunoassays for y-MSH-related peptides were performed with a 1:800 dilution of antiserum Gertrude (Eipper et al., 1983) , using purified AtT-20 16K fragment (Keutmann et al., 1979) as a radiolabeled trace and purified rat intermediate pituitary n-MSH as a standard. Assays were performed in 50 mM sodium phosphate, pH 7.6, containing 0.025% Triton X-100; the final assay volume was 200 ~1, and incubations were carried out for 18 hr at 4°C with approximately 10,000 cpm of 12jI-labeled peptide per tube. Double-antibody immunoprecipitation was used to separate bound from free peptide. Under these conditions, the assay had a midpoint of approximately 200 fmol; maximum net binding was 25%, and nonspecific binding was 0.5%. Antiserum Gertrude demonstrated approximately 70% molar cross-reactivity with purified AtT-20 16K fragment and less than 0.01% molar cross-reactivity with cu-MSH, CLIP, purified mouse fl-LPH, purified rat joining peptide, human ACTH, and camel fl-endorphin.
Radioimmunoassays for amidated joining peptide were performed with a 1:4000 dilution of antiserum Jamie; the antiserum was generated by injection of a female New Zealand White rabbit with a modified syntheticcarboxyl-terminal fragment ofrat-joining peptide coupled with glutaraldehvde to BSA ID-Tyr-Pro-Glu-Pro-Ser-Pro-Am-Glu-NH, or D-Tyr-joining peptide( 12-l 8)NH,; Vega Biotechnologiesj. Assays were oerformed as described. using D-Tvr-ioinina nentide(l2-18)NH, as standard and trace (Eipper and-Mains, unpubisheh observations) . The joining peptide assay demonstrated approximately 70% molar crossreactivity with purified rat-joining peptide and less than 0.01% molar cross-reactivity with joining peptide( 12-l 9) (Vega Biotechnologies), & endorphin, (u-MSH, ACTH, CLIP, purified rat y,-MSH, purified mouse P-LPH, and equine @-MSH.
RP-HPLC analysis of cr-MSH-related material a-MSH-sized material obtained by chromatography on Sephadex G-75 or gel filtration HPLC was dried under reduced pressure, resuspended in 0.1% trifluoroacetic acid, and analyzed on a C,, PBondapak column (Waters Associates; 4 x 250 mm) using the triAuoroacetic~acid/acetonitrile system of Bennett et al. (198 1 b) ; specific elution conditions are indicated in the figure legends. Synthetic marker peptides were purchased from Bachem. The elution positions of synthetic standard peptides were determined in parallel RP-HPLC analyses by monitoring absorbance at 220 nm.
from hypothalamic extracts were dried under reduced pressure, redissolved with 10 mM ammonium formate, pH 2.5, in 30% acetonitrile, and analyzed by ion-exchange HPLC on a Bio-Sil TSK CM-2-SW cation-exchange column (4.6 x 250 mm; Bio-Rad) equilibrated with 35 mM ammonium formate, pH 2.5, in 30% acetonitrile. Samples were eluted with a 60 min linear gradient to 326 mM ammonium formate, pH 2.5, in 30% acetonitrile; the flow rate was 0.7 ml/min. Buffers were prepared from a stock solution of 5 M formic acid titrated to pH 2.5 with ammonium hydroxide. The elution positions of six synthetic p-endorphin standards (Peninsula) were determined by monitoring absorbance at 280 nm (Fig. 1) . As shown in Figure 1 , the @-endorphin-related peptides are eluted primarily on the basis of their charge at pH 2.5 (charge given in brackets): acetyl-&endorphin( l-26) [ + 31, &endor-phin(l-26) 
and &-endorphin(i-26) [+4] are separated by this fractionation procedure indicates that separation is not based solely on charge. Camel and rat P-endorphin(l-31) have identical amino acid sequences (Bennett et al., 1983; Drouin and Goodman, 1980; Li and Chung, 1976); fl-endorphin(l-26) is identical in humans, rat, and camel (Chang et al., 1980) . Application of trace amounts of 'H-labeled AtT-20 &endorphin( l-3 1) (co.05 pmol) to this ion-exchange system, in the absence oftissue extract or carrier protein, resulted in recovery of only 46% of the radioactivity. Inclusion of 2 ng (0.6 pmol) of synthetic &endorphin( l-3 1) along with the 'H-labeled sample increased recovery of radioactivity to levels in excess of 80%. In analyses of hypothalamic extracts, recoveries of j3-endorphin-related immunoreactivity were greater than 70%.
Oxidation of the methionine residue in @-endorphin can occur during the course of tissue extraction and subsequent biochemical analyses (Houahton and Li. 1979: Mains and EiDDer. 1981). Thus. we assaved the ei?ect of methionine oxidation on eluiion of peptides from the ibnexchange (IEX)-HPLC column. Synthetic &-endorphin( l-3 1) and acetyl-&,-endorphin( l-26) were oxidized with hydrogen peroxide and analyzed on the IEX-HPLC column both separately and together with nonoxidized peptide standards. Although the elution positions of oxidized &-endorphin( l-3 1) and acetyl-&-endorphin( l-26) were earlier than those of their corresponding nonoxidized counterparts (data not shown), the altered retention times were not sufficiently different to interfere with peptide identification.
Oxidation of cu-MSH standards
Synthetic CZ-MSH [cY-N-acetyl-ACTH( l-l 3)NH,] and ACTH( l-l 3)NH, were suspended separately (1 mg/ml) in 1 M acetic acid to which 200 pi/ml of 30% hydrogen peroxide was added (O'Donohue et al., 1981) . The reaction was allowed to proceed for 30 min at room temperature, and then an equal volume of 0.1% trifluoroacetic acid was added. The reaction mix was then injected into the C,, PBondapak column, using the trifluoroacetic acid/acetonitrile system of Bennett et al. (1981b) . Isoelectric focusing y-Lipotropin and CLIP-sized immunoreactive material obtained by chromatography on Sephadex G-75 were dried under reduced pressure; samples were dissolved in 5 mM acetic acid containing 0.01% Triton X-100 and applied to a 1 or 2 mm layer of Sephadex IEF resin (Pharmacia) containing 2% ampholytes (pH 2.5-5.0; Eipper and Mains, 1982) . Electrophoresis was allowed to proceed for 16 to 20 hr at 600 V to ensure focusing of peptides. Bands of resin (0.7 cm) were scraped from the glass plate and eluted as indicated in the figure legends. Resin particles were removed by eluting the resin in disposable columns (Evergreen). Samples from one lane of the isoelectric focusing gel were suspended in 2 ml of water to determine the pH profile.
Enzymatic digestions
Digestions with alkaline phosphatase were performed for 4.5 hr at 37°C in 0.1 M NH,HCO, containina 0.5 me/ml BSA and 0.2 units/ml alkaline phosphatase(Sigma type III,42 U/mg); the reaction was stopped by lyophilization (Eipper and Mains, 1982) . Digestions with TPCK-trypsin (Worthington, 236 U/mg) were carried out as previously described (Eipper and Mains, 1977) . When alkaline phosphatase digestions were to 
&-endorphin( l-27), (5) acetyl-&-endorphin( l-3 l), and (6) &endorphin( l-3 1) were mixed and then separated on a Bio-Sil TSK CM-2-SW cationexchange column as described in Materials and Methods. The retention times of the standards were determined by monitoring absorbance at 280 nm. The identities of the peaks were determined by a series of analyses in which the peptides were chromatographed both separately and together.
be carried out subsequently, trypsin was inactivated by addition of phenylmethylsulfonyl fluoride (0.3 mg/ml) and incubation at 37°C for 15 min.
Results

Geljltration analyses of hypothalamic extracts
At the level of gel filtration, the processing of pro-ACTH/endorphin in rat hypothalamus has previously been shown to resemble the pattern in the pars intermedia more closely than the pattern in the pars distalis (Bamea et al., 1982; Dennis et al., 1983a, b; Gramsch et al., 1980; Liotta and Kneger, 1983a, b; Loh et al., 1980) . However, in none of these previous studies was there an attempt to quantitate and simultaneously correlate the processing of a number of the peptides derived from the pro-ACTH/endorphin precursor, including (r-MSH, P-endorphin, CLIP, r-LPH, r-MSH, and joining peptide. Hypothalamic extracts were subjected to size fractionation utilizing Sephadex G-75; fractions were analyzed by radioimmunoassay with antisera directed against several ACTH/endorphin antigenic determinants. Three peaks of amino-terminal ACTH-related immunoreactivity were detected with a general ACTH( l-l 3) immunoassay ( Fig. 2, top ; Table 1 ). The predominant end product was (u-MSHsized. Two additional species with apparent molecular weights of 16,000 and 6500 Da represented less than 3 and 5% of the total ACTH-related immunoreactivity, respectively. ACTHsized material represented approximately 2% of the total ACTHrelated immunoreactivity; while pro-ACTH/endorphin-sized material was not detectable.
Three molecular weight forms of P-endorphin-related immunoreactivity were detected utilizing an antiserum directed against /3-endorphin(lO-19) ( Fig. 2, top ; Table 1 ). The P-endorphin-sized material represented the predominant end product, with minor amounts of both pro-ACTHIendorphin-and P-LPH-sized material ( Fig. 2, top; inset) . As can be seen in Figure 2 (top), approximately equimolar amounts of ACTHand @-endorphin-related material were found (3.4 f 0.3 pmol/ hypothalamus; n = 6).
Two major peaks of carboxyl-terminal, ACTH-related im- The data presented represent a summary of the Sephadex G-75 gel filtration analyses shown in Figure 2 . Data are expressed as percentage of total immunoreactivity recovered for a given radioimmunoassay. The distribution coefficient (K,,) is defined as ( V. -V,)l( V, -VJ, where V. represents the elution volume of a given molecule, and V, and V. represent the total and void volumes, respectively. 0 n.d. = Not detected. munoreactivity ( Fig. 2, middle ; Table l), corresponding to the molecular weights of CLIP [ACTH( l&39)] and glycosylated CLIP, were detected. Whereas the elution position of ACTH is identical to that of glycosylated CLIP, the relatively small amount of ACTH detected with the amino-terminal ACTH assay (Fig.  2, top) , demonstrates that most of the material eluting in this region represents glycosylated CLIP. The percentage of hypothalamic CLIP-related immunoreactive material that corresponds to a glycosylated CLIP-sized molecule is identical to that found for CLIP synthesized in the rat intermediate pituitary (Bennett et al., 1982; Eipper and Mains, 1982) . A minor peak eluted in the region of ACTH biosynthetic intermediate, representing less than 2% of the total ACTH-related immunoreactivity. The antiserum used in this analysis does not cross-react with pro-ACTH/endorphin or CLIP-related peptides lacking the carboxyl-terminal phenylalanine residue. The total amount of carboxyl-terminal ACTH-related immunoreactivity was equimolar to that found for amino-terminal ACTH and p-endorphin-related material (Fig. 2, top) .
Two peaks of r-LPH-related immunoreactivity, corresponding to the molecular weights ofP-LPH and -/-LPH, were detected ( Fig. 2, middle ; Table 1 ). An additional shoulder of y-LPHrelated immunoreactivity, with an apparent molecular weight of 2500, was also detected. This suggests the occurrence of further limited proteolytic processing of hypothalamic r-LPH-related immunoreactive material. Although precise quantitation of rat y-LPH-related immunoreactivity is not possible because of the species specificity of the assay, the percentage of @-LPHsized molecules, compared with total immunoreactivity, was the same whether the y-LPH or /3-endorphin immunoassay was used. If one equates the amount of ,&LPH-sized material per hypothalamus detected by the y-LPH (Fig. 2, middle) and P-endorphin (Fig. 2, top) assays, the total amount of y-LPH-related material per hypothalamus is equimolar to the total amount of fl-endorphin-related material per hypothalamus.
The amino-terminal 94 is composed of amino acids of pro-ACTH/endorphin, a cystine-rich region at the extreme amino terminus, a region referred to as y,-MSH in the middle, and a joining or "hinge" peptide region at the extreme carboxyl terminus (Drouin and Goodman, 1980; Nakanishi et al., 1979) . The carboxyl terminus of rat-joining peptide contains a potential amidation site (-Glu-Gly-Lys-Arg-), and amidated joining peptide has been identified in extracts of human pituitary (Seidah et al., 1981) . In hypothalamic extracts, one major peak, corresponding to the size of rat-joining peptide (1883 Da), was detected with an immunoassay specific for amidated joining peptide ( Fig. 2, bottom (Eipper and Mains, unpublished data) resulted in an identical gel filtration profile; similar amounts of immunoreactive material were detected with both the general and amide-specific joining peptide assays, suggesting that the joining peptide-sized immunoreactive material is largely a-amidated. The total amount of joining peptide-related immunoreactivity was roughly equimolar to that of other ACTH/endorphin-derived peptides (Fig. 2, top, middle) .
Analyses with an antiserum directed against r-MSH detected two peaks of r-MSH-related immunoreactivity (Fig. 2, bottom ; Table 1 ) corresponding to the elution positions of glycosylated T,-MSH and of a molecule with an apparent molecular weight of 7100 (K., = 0.44). In three separate analyses, the species of Kd 0.44 constituted an average of 18% of the total r-MSHrelated immunoreactivity. The molecular weight difference between the species of Kd 0.39 detected with the joining peptide Figure 3 . Gel filtration analysis of hypothalamic extracts using modification-specific LU-MSH antisera. Tissue extracts from 38 adult male rat hypothalami were fractionated on Sephadex G-75 as described in Materials and Methods. Aliquots (SO-300 ~1) were analyzed by radioimmunoassay utilizing a general amino-terminal ACTH assay (0). an amide-directed (u-MSH assay (0), and an acetyl-directed (u-MSH assay (A). Arrows mark the elution positions ofeither )H-labeled peptides obtained from a mouse corticotropic tumor cell line (AtT-20) or lz51-labeled synthetic peptides. Recovery of general amino-terminal ACTH-related immunoreactivity was 9OOVo. synthesized by pituitary melanotropes is glycosylated pro-ACTH/ endorphin(l-74), the remainder being cleaved to form glycosylated Lys--r,-MSH and pro-ACTH/endorphin( 149) (Seger and Bennett, 1984) .
Characterization of a-MSH-sized material
Although earlier studies reported the presence of significant amounts of authentic (u-MSH [cY-N-acetyl-ACTH( l-l 3)NH,] in whole brain extracts (Loh et al., 1980; O'Donohue et al., 198 l) , Figure 4 . Reverse-phase HPLC analysis of hypothalamic cr-MSH-sized material. A pool of cu-MSH-sized material (K, 0.79-0.9 1) from extracts of 26 adult male rat hypothalami was analyzed on a Waters C,, PBondapak column equilibrated with 4% acetonitrile in 0.1% trifluoroacetic acid. Peptides were eluted with a linear gradient from 4 to 24% acetonitrile in 0.1% trifluoroacetic acid over 10 min, followed by a linear gradient from 24 to 48% acetonitrile in 0.1% trifluoroacetic acid over 50 min. more recent studies have reported the presence of exclusively desacetyl-cY-MSH [ACTH( l-l 3)NH,] in extracts of whole brain (Evans et al., 1982) and extracts of rat hypothalamus (Dennis et al., 1983a , b, Evans et al., 1982 Geis et al., 1984; Liotta et al., 1984; Smith et al., 1982; Turner et al., 1983) . Three LU-MSH antisera directed against different c~-MSH antigenic determinants were used for initial analysis of hypothalamic extracts fractionated by gel filtration (Fig. 3) . The general amino-terminal ACTH antiserum demonstrated the expected peak of a-MSH-sized immunoreactive material, representing 8 5% of the total ACTH-related immunoreactivity (similar to Fig. 2, top) . When the a-MSH-sized material was analyzed with an amidedirected LU-MSH antiserum, similar amounts of immunoreactive material were detected. An acetyl-directed (r-MSH antiserum detected only 13% as much immunoreactive material as the and immunoreactivity were 72 and 77%, respectively. Arrows mark the elution positions of P-endorphin(l-26) (220 mM NaCl), @-endorphin(l-27) (270 mM NaCl), and 6-endorphin(13 1) (360 mM NaCl). The elution positions of AC-B-endorphin(l-26), , and AC-@-endorphin( l-3 1) correspond to fractions 3 1, 39, and 6 1, respectively. fi-Endoxphin( l-3 l), @-endorphin( l-27), and &endorphin( l-26) represented 56, 30, and 1 l%, respectively, of the total hypothalamic @-endorphin-related immunoreactive material.
other two antisera. These results suggest that hypothalamic a-MSH-sized material is fully a-amidated at its carboxyl terminal, whereas only a small percentage of the molecules are LY-N-acetylated. In order to more fully characterize the cr-MSH-sized material from rat hypothalamus, the cu-MSH-sized peptides were analyzed by RP-HPLC in the trifluoroacetic acid/acetonitrile system of Bennett et al. (1981b) , which separates cu-MSH-related molecules primarily by their state of acetylation (Fig. 4) . The major immunoreactive cu-MSH-related peptides were eluted with the retention times of ACTH(l-13)NH, or its sulfoxide and represented 85% of the total a-MSH-related immunoreactivity. Smaller peaks eluted at the positions of (r-MSH [cr-N-acetyl-ACTH( l-l 3)NH,] and its sulfoxide represented approximately 13% of the Lu-MSH-related immunoreactive material. Radioimmunoassays of the same fractions with the amide-specific (u-MSH antiserum gave identical results, and assays with the acetylspecific (u-MSH antiserum further confirmed the identification. In seven separate analyses of a-MSH-sized material by RP-HPLC, the amount of immunoreactive material corresponding to (Y-MSH or its sulfoxide varied between 3 and 13% of the total cu-MSH-related immunoreactivity. The occurrence of substantial amounts of the sulfoxides of both ACTH( l-l 3)NH, and (Y-MSH in hypothalamic extracts, rather than representing the actual physical form of these molecules as they exist in hypothalamic tissue, probably results from oxidation during the course of biochemical manipulation.
Characterization of (?-endorphin-sized material Zakarian and Smyth (1982a, b) have reported region-specific processing variations of /I-endorphin throughout the CNS, revealing two contrasting patterns of a-N-acetylation, which suggest the gradual increase of such acetylation from hypothalamus to midbrain. Weber et al. (198 1) have found that less than 2% of the p-endorphin-sized immunoreactive material from extracts of normal rat brain was cy-N-acetylated. The P-endorphinsized material from rat hypothalamus was characterized by ionexchange chromatography on a column of SP-Sephadex (Fig.  5) . A trace amount of 3H-labeled &endorphin( l-3 1) obtained from a mouse pituitary corticotropic tumor cell line (AtT-20) was included in each sample to mark the elution position of &endorphin( l-3 1). We detected three peaks of&endorphin immunoreactivity with elution positions corresponding to those of &endorphin( l-3 l), &endorphin( l-27), and @-endorphin( l-26) or acetyl-@-endorphin( l-27) (Fig. 5) ; the latter two peptides are not resolved by this system. Owing to the absence of significant amounts of the cy-N-acetylated derivatives of /3-endorphin( l-3 1) and &endorphin( l-26), the earliest-eluted form of /3-endorphin-related material was tentatively identified as @-endorphin( l-26), rather than acetyl-D-endorphin( l-27).
In the analysis shown, the cu-N-acetylated forms of @-endorphin-primarily acetyl-P-endorphin( l-3 1)-represented less than 2% of the total P-endorphin-related immunoreactivity. In four separate analyses, the amount of @-endorphin-related immunoreactive material corresponding to the expected elution position of cr-N-acetyl-&endorphin( l-3 1) varied between 1 and 6%. Full-length P-endorphin( l-3 1) (acetylated and not) consistently acounted for about 60% of the p-endorphin-sized immunoreactive material, with the remaining 40% accounted for by material that had undergone carboxyl-terminal proteolytic processing. The extent of carboxyl-terminal proteolysis was somewhat more variable, the ratio of /3-endorphin(l-27) to @endorphin( l-26) varying between 1 and 2.
Although ion-exchange chromatography utilizing SP-Sephadex represents an effective means for separating various a-Nacetylated and carboxyl-terminal shortened forms of P-endorphin, the presence of relatively high concentrations of NaCl in the column fractions may interfere with subsequent immu- of 17 adult male rat hypothalami was dried under reduced pressure and resuspended in 10 mM ammonium formate, pH 2.5, in 30% acetonitrile;
a 3H-labeled sample of AtT-20 p-endorphin(l-31) was added as an internal standard (10.05 pmol). The sample was analyzed by IEX-HPLC as described in Materials and Methods. For immunoassays, aliquots (100 ~1) of 0.5 ml fractions were pooled by fives (fractions l-25 and 86-95) or pairwise (fractions 26-85), dried under reduced pressure, and dissolved in 100 mM sodium phosphate, pH 7.6, containing 1% Triton X-100. The elution position of the 'H-labeled marker was determined by liquid scintillation counting of 50 pl aliquots of each fraction. Recovery of radioactivity was 73%. Arrows mark the elution positions of ,&endorphin(l-26), fl-endorphin( l-27), and p-endorphin( l-3 1). The elution positions of acetyl-fiendorphin( l-26), acetyl-fi-endorphin( l-27), and acetyl+-endorphin( l-3 1) correspond to fractions 37,42, and 68, respectively. fl-Endorphin( l-3 l), acetyl-fl-endorphin(l-31), &endorphin(l-27), and fl-endorphin(l-26) represented 57, 7, 19, and 14%, respectively, of the total hypothalamic flendorphin-related immunoreactive material. noassay analyses. This problem is particularly evident when attempting to analyze a tissue such as hypothalamus, whose fl-endorphin content is low when compared to the pituitary. Separation of the various forms of /3-endorphin by IEX-HPLC with volatile buffers was investigated as an alternative fractionation method (Fig. 1) . Whole hypothalamic extracts or ,&en-dorphin-sized material were analyzed by ion-exchange HPLC on a cation-exchange column; peptides were eluted from the column with an increasing concentration of ammonium formate, pH 2.5, in 30% acetonitrile (Fig. 6) . Four major peaks of p-endorphin-related immunoreactivity, corresponding to the elution positions of p-endorphin( l-3 l), acetyl-p-endorphin( l-3 l), fi-endorphin( l-27), and &endorphin( l-26), were detected (Fig. 6) . Minor peaks corresponded to the elution positions of acetyl-&endorphin( l-26) (fraction 37) and acetyl-fi-endorphin( l-27) (fraction 42). Results obtained using IEX-HPLC were consistent with those previously obtained with SP-Sephadex, demonstrating that fully bioactive p-endorphin( l-3 1) accounts for more than half of the total hypothalamic P-endorphin-related immunoreactivity.
Characterization of CLIP-sized material
Previous studies have demonstrated that approximately twothirds of the CLIP-sized material in the rat intermediate pituitary is phosphorylated at Ser31 (Bennett et al., 1982; Browne et al., 198 1 a; Eipper and Mains, 1982) . In order to determine the extent of phosphorylation of the CLIP-related molecules in rat hypothalamus, CLIP-sized material was fractionated by isoelectric focusing (Fig. 7, upper) . A trace amount of jH-labeled CLIP obtained from primary cultures of rat neurointermediate lobe was included in each sample as an internal standard. Two peaks of CLIP-related immunoreactivity, which focused with phosphorylated rat CLIP at pH 4.12 and with nonphosphorylated rat CLIP at pH 4.47, were detected; the theoretical isoelectric focusing points for the phosphorylated and nonphosphorylated forms of rat CLIP are 4.08 and 4.43, respectively (Eipper and Mains, 1982) . The minor peaks of immunoreactivity focusing at pH 3.68 and pH 3.05, which did not correspond to any tritium counts from the pituitary standard, may be due to the presence of glycosylated CLIP in the original G-75 gel filtration pool. Based on the distribution of immunoreactivity in Figure 7 (top), >90% of the hypothalamic CLIP-sized material is phosphorylated. In four separate analyses, the extent of phosphorylation of hypothalamic CLIP-sized material varied between 83 and 93%. Alkaline phosphatase treatment was used to verify the hypothesis that the major difference between the two isoelectric forms of CLIP was the presence of a phosphate residue (Fig. 7,  bottom) . When hypothalamic CLIP-sized material was treated with alkaline phosphatase before application to the isoelectric focusing gel, a single major peak of CLIP-related immunoreactivity, focused at pH 4.47, was obtained; alkaline phosphatase treatment also converted the radiolabeled pituitary CLIP internal standard into a single peak, focusing at pH 4.47. The quantitative conversion of the more acidic form of hypothalamic CLIP to the more basic form by treatment with alkaline phosphatase demonstrates that the major difference between these isoelectric forms is the presence of a phosphate moiety.
In order to confirm the extent of phosphorylation of CLIP in hypothalamic tissue extracts, tryptic digests of control and alkaline phosphatase-treated CLIP-sized material were analyzed as in Figure 7 (data not shown). Approximately 82% of the CLIP-related immunoreactivity focused at pH 3.12, close to the theoretical isoelectric point for phosphorylated ACTH(22-39) (PI = 3.18), with the remainder focusing at pH 3.70, which is near the theoretical isoelectric point for nonphosphorylated . Isoelectric focusing of hypothalamic CLIP-sized immunoreactive material. A pool of CLIP-sized material (& 0.69-0.79 ) from extracts of 48 adult rat hypothalami was dried, resuspended in 0.1 M NH,HCO, containing 0.5 mg/ml BSA; a sample of 3H-phenylalanine-labeled CLIP (10.08 pmol), obtained from primary cultures of rat intermediate pituitary, was added. The sample was then divided into equal aliquots; one aliquot was analyzed directly (top) and the other was digested with alkaline phosphatase before analysis (bottom). The samples were applied to a 2 mm layer of Sephadex IEF resin (pH 2.5-5.0) in the region of slice 25. Samples were eluted from the resin in 2 ml of 25 mM NH,HCO,, 0.1 mg/ml BSA, and 0.005% NP-40. The isoelectric focusing point of the 'H-labeled intermediate pituitary CLIP was determined by liquid scintillation counting of 700 pl aliquots of each fraction. For immunoassays, samples were dried under reduced pressure and dissolved in 100 mM sodium phosphate, pH 7.6, containing 1% Triton X-100. Recoveries of immunoreactivity for the control and alkaline phosphatase-treated sample were 99% and 84%, respectively.
ACTH(22-39) (PI = 3.52). Alkaline phosphatase treatment of the carboxyl-terminal tryptic peptides resulted in a single major peak, focusing at pH 3.70. The results obtained by analysis of intact CLIP or the carboxyl-terminal tryptic peptide of CLIP were in agreement.
Characterization of y-LPH-sized material Hypothalamic y-LPH-sized immunoreactive material was fractionated by isoelectric focusing in order to determine whether it is subjected to additional posttranslational modifications, such as acetylation, phosphorylation, or sulfation, which would affect its isoelectric point (Fig. 8) . A single major peak, representing 74% of the total y-LPH-related immunoreactivity, focused at pH 4.32, the theoretical isoelectric focusing point for rat y-LPH (Eipper and Mains, 1982) . A minor peak focusing at pH 4.44, representing approximately 10% of the total y-LPH-related immunoreactivity, could result from the removal of either the carboxyl-terminal aspartic acid or the amino-terminal glutamic acid residues. Addition of an cu-N-acetyl, phosphate, or sulfate moiety would be expected to shift the isoelectric point of the modified -y-LPH to approximately 4.17. The majority of the hypothalamic y-LPH-sized material is indistinguishable from -y-LPH isolated from the pars intermedia, and does not appear to be subject to additional posttranslational processing.
Discussion
Published reports on the ACTH and P-LPH regions of the pro-ACTH/endorphin precursor indicate that the proteolytic processing pattern in the hypothalamus closely resembles that in the intermediate pituitary (Bamea et al., 198 1, 1982; Gramsch et al., 1980; Lob et al., 1980; 01~011 et al., 1978; Seizinger et al., 1984) . In the present studies, this similarity was extended to the amino-terminal region of pro-ACTH/endorphin; at the level of gel filtration, material of the size of joining peptide and glycosylated y,-MSH represented major end products. The major peptide products found in the rat hypothalamus are diagrammed in Figure 9 ; the cystine-rich amino-terminal region was not investigated in these studies and is therefore not represented. The endoproteolytic processing events that proceed essentially to completion all involve cleavage at a -Lys-Arg- of 18 adult male rat hypothalami was 1 dried under reduced pressure, resusfpended in 5 mM acetic acid, and applied to a 1 mm layer of Sephadex IEF (pH 2.5-5); samples were applied in the region of slice 25. Electrophoresis was allowed to proceed for 19 hr at 600 V and the bands of resin were eluted in 3 ml of 50 mM NH,HCO, containing 1 mp/ ml BSA and 0.1% NP-40. For immunoassays, samples were treated as described in Figure 7 ; recovery of -/-LPHrelated immunoreactivity was 120%.
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SLICE NUMBER sequence, except for the cleavage that generates the amino terminus of joining peptide, which involved cleavage at an -ArgArg-site. The proteolytic processing at the -Arg-Lys-sequence separating the cystine-rich amino-terminal region from y,-MSH proceeded only partially, as in the pars intermedia (Seger and Bennett, 1984) . The cu-N-acetylation of ACTH( l-l 3)NH, results in a 15fold increase in melanophore stimulating activity, enhances potency in behavioral tests, such as excessive grooming and visual discrimination, and decreases ability to block opiate-induced analgesia Guttmann and Boissonnas, 1961; O'Donohue et al., 198 1, 1982) . The amino-terminal acetylation of P-endorphin destroys its opiate activity (Akil et al., 198 1; Smyth et al., 1979) . The presence or absence of a posttranslational modification such as a-N-acetylation thus provides a mechanism for modulating the hormonal or neurosecretory output of neurons expressing the same gene.
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Previous studies have not reached a consensus regarding the extent to which a-MSH-and /3-endorphin-related material in extracts of rat hypothalamus or whole brain is a-N-acetylated (Loh et al., 1980; O'Donohue et al., 1982) . The biochemical analyses presented here demonstrate that about 10% of both the hypothalamic LU-MSH-and p-endorphin-related material represents a-N-acetylated material (Figs. 3-6 ). These results are in agreement with a majority of the previously published works regarding the limited extent to which both CY-MSH and ,&en-dorphin are acetylated in the hypothalamus (Evans et al., 1982; Geis et al., 1984; Liotta et al., 1984; Smith et al., 1982; Turner et al., 1983; Weber et al., 1981; Smyth, 1979, 1982a, b) . If, as has been suggested for the intermediate pituitary (Chappell et al., 1982; Glembotski, 1982) , a single secretory granule-associated acetyltransferase is responsible for the amino-terminal acetylation of both (u-MSH and /3-endorphin, parallel alteration in the acetylation of both products would be -Gly -Lyr-Lyr-Arg-Arg- Figure 9 . Major products of pro-ACTH/endorphin processing in rat hypothalamus. A schematic diagram of the rat pro-ACTH/endorphin molecule is depicted (Drouin et al., 1980) . It shows the major end products of pro-ACTH/endorphin processing in rat hypothalamus. The amino acid sequences at potential paired basic amino acid cleavage sites and at potential amidation sites are designated. The N-linked oligosaccharide groups within y,-MSH and CLIP, the phosphate moiety within CLIP, and the site of cleavage producing the amino terminus of T,-MSH (Lys,,-ra-MSH) have been positioned by analogy to the pituitary (Bennett et al., 1981a; Browne et al., 1981b; Eipper and Mains, 1977) .
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expected. Approximately 80% of the cu-MSH-and 60% of the @-endorphin-related material in extracts of rat or guinea pig caudal medulla, containing the region of the nucleus of the solitary tract, is a-N-acetylated (Dores et al., in press ). Liotta et al. (1984) , using in vivo labeling, reported production of only nonacetylated forms of both CY-MSH and @-endorphin by neurons in the region of the arcuate nucleus. These two observations suggest that the cu-N-acetyl-ACTH( l-l 3)NH, and cu-N-acetylated P-endorphin in the hypothalamic region may be present in nerve fibers or terminal fields originating in the nucleus tractus solitarius. Alternatively, a subpopulation of ACTH/endorphin arcuate neurons projecting to specific target areas may contain peptide products different from those elaborated by the majority. Limited carboxyl-terminal proteolysis of p-endorphin( l-3 1) has pronounced effects on opiate activity (Geisow et al., 1977; Hammonds et al., 1984; Smyth et al., 1979) . In opiate bioassays, @endorphin( l-27) has been shown to be .approximately equipotent to @-endorphin(l-31) in inhibiting the contraction of guinea pig myenteric plexus (M&night et al., 1983) . In the CNS, the analgesic potency of P-endorphin(l-27) is only 2% that of p-endorphin( l-3 l), but this decreased opiate bioactivity is only partially reflected in a decreased affinity for opiate receptors and makes p-endorphin( l-27) a potent antagonist ofp-endorphin( l-3 1) (Hammonds et al., 1984) .
The results presented here are in agreement with previous studies demonstrating that p-endorphin( l-3 1) represents the predominant end product in the hypothalamus (Dennis et al., 1983a; Liotta et al., 1984; Smyth, 1979, 1982a, b) . Ion exchange chromatography (Figs. 5 and 6 ) has demonstrated that, in addition to @endorphin( l-3 l), p-endorphin( l-27) and &endorphin( l-26) represent significant end products. The results of in vivo biosynthetic labeling studies suggested that only intact &endorphin( l-3 1) was a major product peptide of arcuate ACTH/endorphin neurons (Liotta et al., 1984) ; however, assuming that the kinetics of carboxyl-terminal shortening are comparable in hypothalamus and pars intermedia, the labeling period studied by Liotta et al. (1984) would not have been sufficient to determine the final extent of carboxyl-terminal proteolytic processing of p-endorphin (Glembotski, 1982) . As with cu-N-acetylation of P-endorphin, the degree to which the carboxyl-terminally shortened forms of /3-endorphin are produced may represent one of the regulatory mechanisms by which normal levels of opiate activity are maintained within the CNS.
The phosphorylation of corticotropin-related peptides has been shown to vary widely among species and also among tissues within a given species; one-fifth of the mouse pituitary ACTH and CLIP, one-third of the human pituitary ACTH, one-half of rat anterior pituitary ACTH, and two-thirds of rat intermediate pituitary CLIP are phosphorylated (Bennett et al., 1982; Eipper and Mains, 1982; Mains and Eipper, 1983) . Isoelectric focusing analyses have demonstrated that 83 to 93% of rat hypothalamic CLIP-sized immunoreactive material is phosphorylated (Fig.  7) . Glycosylation of corticotropin-related peptides has also been shown to be species-specific; whereas approximately two-thirds of the corticotropin-related peptides in the mouse pituitary are glycosylated, only one-sixth are glycosylated in the rat (Bennett et al., 1982; Eipper and Mains, 1982) . The present study demonstrates that approximately 20% of the hypothalamic carboxylterminal ACTH-related immunoreactivity corresponds to the molecular weight ofglycosylated CLIP (Fig. 2, middle) , the same percentage found in rat intermediate pituitary (Bennett et al., 1982; Eipper and Mains, 1982) . The physiological consequences of such limited glycosylation and extensive phosphorylation remain to be determined. Equimolar amounts of CLIP-related molecules and other pro-ACTH/endorphin-derived peptides were found in the hypothalamus (Fig. 2, middle) . Although the carboxyl-terminal ACTH antiserum used in these analyses does not cross-react with ACTH( 18-38)-related molecules, this result suggests that carboxyl-terminally shortened CLIP does not represent a major hypothalamic product.
As summarized in Figure 9 , the differences in the processing patterns in the intermediate pituitary and the hypothalamus might be explained by differences in only three enzymatic activities involved in posttranslational processing. Hypothalamic ACTH/endorphin neurons, similar to intermediate pituitary melanotropes at the level of gross proteolytic processing, appear more like anterior pituitary corticotropes in exhibiting relatively little a-N-acetylation of wMSH and P-endorphin. Carboxylterminal proteolysis of p-endorphin, which does not occur to any significant extent in corticotropes, occurs to a lesser extent in hypothalamic neurons than in melanotropes. In addition, the hypothalamic neurons exhibit more extensive phosphorylation of CLIP than is observed in either melanotropes or corticotropes. The fact that nearly equimolar amounts of /3-endorphin-, T-LPH-, a-MSH-, CLIP-, and joining peptide-related immunoreactivity are found in the hypothalamus, and that such molecules have been localized to the same secretory granules (Barnea et al., 198 1; Pelletier, 1979) , indicates that significant amounts of each of the various product peptides are secreted together in response to appropriate stimuli, and that the coordinate effects of the various peptides on the same and different target neurons must be considered.
